Didanosine

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Thursday, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."

BlueCat taps industry pioneers for IT community's first annual DDI Day celebration

Retrieved on: 
Tuesday, April 6, 2021
KDDI, Paul Mockapetris, Didanosine, Au, DDI

TORONTO, April 06, 2021 (GLOBE NEWSWIRE) -- BlueCat, the Adaptive DNSTM company, announced today that it will be hosting the first annual, industry-wide celebration called DDI Day on April 13th.

Key Points: 
  • TORONTO, April 06, 2021 (GLOBE NEWSWIRE) -- BlueCat, the Adaptive DNSTM company, announced today that it will be hosting the first annual, industry-wide celebration called DDI Day on April 13th.
  • DDI Day recognizes the heroic efforts of IT professionals who keep these services working, and consequently, our world moving.
  • DDI Day celebrations will feature:
    A panel discussion by industry pioneers Paul Mockapetris, Ralph Droms, and Russ White.
  • An open invitation for the public to recognize a DDI professional via social networks using the hashtags #DDIHero #DDIDay.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)

Retrieved on: 
Friday, March 12, 2021
Legal, Professional services, Health sciences, Health, Finance, Clinical research, Pharmaceutical industry, Clinical trial, Design of experiments, Drug discovery, Class action, Food and Drug Administration, Investor, Didanosine

Investors suffering losses on their Athenex investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Athenex investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • As a result, the FDA had recommended that Athenex conduct additional clinical trials and employ certain risk mitigation strategies to improve toxicity.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Strategies to Optimize Your Drug-Drug Interaction Program, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Friday, November 20, 2020
Health sciences, Life sciences, Drug discovery, Pharmaceutical industry, Pharmaceutical sciences, Pharmacy, Bristol-Myers Squibb, Didanosine, Hepatotoxins, Simulation, Pharmacokinetics, Preclinical development

Join this educational webinar to hear three specialists share their expertise on how sponsors can optimize their DDI evaluation process, spanning from preclinical to clinical.

Key Points: 
  • Join this educational webinar to hear three specialists share their expertise on how sponsors can optimize their DDI evaluation process, spanning from preclinical to clinical.
  • Population pharmacokinetics (PopPK) strategies will then be presented to explain how modeling and simulation can help evaluate DDI risk and support labeling.
  • For more information, or to register for this event, visit Strategies to Optimize Your Drug-Drug Interaction Program.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

CURE Pharmaceutical Announces Exercise of Warrants for Cash Proceeds of Approximately $1.4 Million and Completes Earn Out Related to 2019 Acquisition

Retrieved on: 
Tuesday, June 9, 2020
Food and Drug Administration, United States Public Health Service, Didanosine, Health

The warrant exercise is part of the completion of all earn-out arrangements and obligations related to CUREs acquisition of Chemistry Holdings on May 14, 2019.

Key Points: 
  • The warrant exercise is part of the completion of all earn-out arrangements and obligations related to CUREs acquisition of Chemistry Holdings on May 14, 2019.
  • This is a win/win for Chemistry Holdings and CURE stockholders, said Rob Davidson, CEO of CURE.
  • With the acquisition of Chemistry Holdings, CURE obtained valuable proprietary formulation and dosage technology that expanded the CUREfilm platform with additional patents and know-how for improving drug absorption, efficacy, palatability, texture and portability.
  • CURE has an FDA- and DEA- registered, cGMP manufacturing facility and is a pioneering developer of CUREform, a patented drug delivery platform.

Coronavirus (COVID-19) Update: FDA Publicly Shares Antibody Test Performance Data From Kits as Part of Validation Study

Retrieved on: 
Thursday, June 4, 2020
Health, Medical specialties, Federally Funded Research and Development Centers, Clinical research, Pharmaceutical industry, Antibody, Glycoproteins, Immunology, National Cancer Institute, Food and Drug Administration, Didanosine, ELISA

SILVER SPRING, Md., June 4, 2020 /PRNewswire/ --Today, the U.S. Food and Drug Administration publicly posted test performance data from four more antibody, or serology, test kits on open.fda.gov from its independent performance validation study effort with the National Institutes of Health's (NIH) National Cancer Institute (NCI).

Key Points: 
  • SILVER SPRING, Md., June 4, 2020 /PRNewswire/ --Today, the U.S. Food and Drug Administration publicly posted test performance data from four more antibody, or serology, test kits on open.fda.gov from its independent performance validation study effort with the National Institutes of Health's (NIH) National Cancer Institute (NCI).
  • Additional performance data will be made available as the FDA reviews and determines if any further actions are appropriate for those test kits prior to publication.
  • Data from an antibody test kit were first posted on May 4, 2020.
  • NCI will continue to play its part by examining these kits and generating important data that supports FDA's decision-making."

Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)

Retrieved on: 
Monday, January 6, 2020
Health, Articles, Life sciences, Pharmacokinetics, Pharmacy, Food and Drug Administration, Didanosine

Continued communication with FDA is essential for the development of SLS-002 in this high unmet need of ASIB in MDD.

Key Points: 
  • Continued communication with FDA is essential for the development of SLS-002 in this high unmet need of ASIB in MDD.
  • We are diligently striving to advance the program forward as we share the Phase I data from the ongoing studies throughout the first quarter, said Raj Mehra, Ph.D., Chairman and CEO of Seelos.
  • Data from the ongoing Phase I studies of SLS-002 to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interactions (DDI) is expected throughout the first quarter of 2020.
  • Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct.

US$ 1.5 Bn DDI Market to Witness Steady Growth in 2028 - Future Market Insights

Retrieved on: 
Friday, March 15, 2019
Mobile technology, Bring your own device, Mobile device management, Didanosine, Telecommunications, Technology

According to a new Future Market Insights' study, SMEs are rapidly emerging as high-potential end use consumers for DDI services and solutions providers.

Key Points: 
  • According to a new Future Market Insights' study, SMEs are rapidly emerging as high-potential end use consumers for DDI services and solutions providers.
  • Furthermore, DDI adoption is most likely witness an above-average rate within MEA over the coming years.
  • Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-9033
    Demand for DDI solutions will continue to account for more than 50% of the total market value.
  • According to the report, constantly increasing popularity of the BYOD (Bring your own device) trend at workplaces will prominently assist the growth of DDI market in the near future.

US$ 1.5 Bn DDI Market to Witness Steady Growth in 2028 - Future Market Insights

Retrieved on: 
Friday, March 15, 2019
Mobile technology, Bring your own device, Mobile device management, Didanosine, Telecommunications, Technology

According to a new Future Market Insights' study, SMEs are rapidly emerging as high-potential end use consumers for DDI services and solutions providers.

Key Points: 
  • According to a new Future Market Insights' study, SMEs are rapidly emerging as high-potential end use consumers for DDI services and solutions providers.
  • Furthermore, DDI adoption is most likely witness an above-average rate within MEA over the coming years.
  • Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-9033
    Demand for DDI solutions will continue to account for more than 50% of the total market value.
  • According to the report, constantly increasing popularity of the BYOD (Bring your own device) trend at workplaces will prominently assist the growth of DDI market in the near future.

Automotive Titling Services Veteran Joins DDI Technology

Retrieved on: 
Wednesday, January 23, 2019
KDDI, Au, DDI, Didanosine

Moore, the previous Chief Operating Officer of VINtek and a GM Chairman's Honors Award Winner, brings over 20 years of experience in automotive title and registration services.

Key Points: 
  • Moore, the previous Chief Operating Officer of VINtek and a GM Chairman's Honors Award Winner, brings over 20 years of experience in automotive title and registration services.
  • According to Glenn Thames, President and CEO of DDI Technology, "Moore is joining the DDI team at a perfect time to catapult business opportunities as we expand our products and services for our growing customer base."
  • Moore will also be involved with corporate marketing initiatives to increase communications and awareness of DDI Technology's complete package of services that have been specifically designed to benefit automotive lenders.
  • DDI Technology looks forward to Moore's expertise, vision and leadership heading into 2019.